{
    "info": {
        "nct_id": "NCT04423029",
        "official_title": "A Phase 1/1b, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications",
        "inclusion_criteria": "* Advanced/metastatic solid tumors, for which no standard therapy exists or standard therapy has failed among the following tumor types: melanoma, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell, urothelial, gastric, esophageal, cervical, hepatocellular, merkel cell, cutaneous squamous cell carcinoma, renal cell, endometrial, triple-negative breast, ovarian, and prostate\n* ECOG performance status of 0 or 1\n* Clinical or radiological evidence of disease\n* Adequate hematological, hepatic and renal function\n* Anticoagulants are required for the following: Khorana Risk Score ≥ 2 or as assessed by Investigator as being at high risk for venous thromboembolism (VTE) or history of VTE ≥ 6 months from enrollment\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Concurrent anticancer treatment (with the exception of palliative bone directed radiotherapy), immune therapy, or cytokine therapy (except for erythropoietin), major surgery (excluding prior diagnostic biopsy), concurrent systemic therapy with steroids or other immunosuppressive agents, or use of any investigational drug within 28 days before the start of study treatment\n* Prior treatment with DF6002, recombinant human interleukin-12 (rhIL-12)-directed therapy, or any drug containing an interleukin-12 (IL-12) moiety\n* Previous malignant disease other than the current target malignancy within the last 3 years, with the exception of basal or squamous cell carcinoma of the skin, localized prostate cancer or cervical carcinoma in situ\n* Rapidly progressive disease\n* Serious cardiac illness or medical conditions\n* Known diagnosis of antiphospholipid syndrome or clinically significant hereditary thrombophilia\n\nOther protocol-defined inclusion/exclusion criteria apply",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate hematological, hepatic and renal function",
            "criterions": [
                {
                    "exact_snippets": "Adequate hematological ... function",
                    "criterion": "hematological function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... hepatic ... function",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... renal function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG performance status of 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Anticoagulants are required for the following: Khorana Risk Score ≥ 2 or as assessed by Investigator as being at high risk for venous thromboembolism (VTE) or history of VTE ≥ 6 months from enrollment",
            "criterions": [
                {
                    "exact_snippets": "Khorana Risk Score ≥ 2",
                    "criterion": "Khorana Risk Score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "as assessed by Investigator as being at high risk for venous thromboembolism (VTE)",
                    "criterion": "risk for venous thromboembolism (VTE)",
                    "requirements": [
                        {
                            "requirement_type": "risk assessment",
                            "expected_value": "high"
                        }
                    ]
                },
                {
                    "exact_snippets": "history of VTE ≥ 6 months from enrollment",
                    "criterion": "history of venous thromboembolism (VTE)",
                    "requirements": [
                        {
                            "requirement_type": "history duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Advanced/metastatic solid tumors, for which no standard therapy exists or standard therapy has failed among the following tumor types: melanoma, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell, urothelial, gastric, esophageal, cervical, hepatocellular, merkel cell, cutaneous squamous cell carcinoma, renal cell, endometrial, triple-negative breast, ovarian, and prostate",
            "criterions": [
                {
                    "exact_snippets": "Advanced/metastatic solid tumors",
                    "criterion": "solid tumor stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "for which no standard therapy exists or standard therapy has failed",
                    "criterion": "standard therapy status",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "failure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "among the following tumor types: melanoma, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell, urothelial, gastric, esophageal, cervical, hepatocellular, merkel cell, cutaneous squamous cell carcinoma, renal cell, endometrial, triple-negative breast, ovarian, and prostate",
                    "criterion": "tumor type",
                    "requirements": [
                        {
                            "requirement_type": "inclusion",
                            "expected_value": [
                                "melanoma",
                                "non-small cell lung cancer",
                                "small cell lung cancer",
                                "head and neck squamous cell",
                                "urothelial",
                                "gastric",
                                "esophageal",
                                "cervical",
                                "hepatocellular",
                                "merkel cell",
                                "cutaneous squamous cell carcinoma",
                                "renal cell",
                                "endometrial",
                                "triple-negative breast",
                                "ovarian",
                                "prostate"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinical or radiological evidence of disease",
            "criterions": [
                {
                    "exact_snippets": "Clinical or radiological evidence of disease",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "evidence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "evidence_type",
                            "expected_value": [
                                "clinical",
                                "radiological"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "Other protocol-defined inclusion/exclusion criteria apply",
            "criterions": [
                {
                    "exact_snippets": "Other protocol-defined inclusion/exclusion criteria apply",
                    "criterion": "other protocol-defined inclusion/exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Concurrent anticancer treatment (with the exception of palliative bone directed radiotherapy), immune therapy, or cytokine therapy (except for erythropoietin), major surgery (excluding prior diagnostic biopsy), concurrent systemic therapy with steroids or other immunosuppressive agents, or use of any investigational drug within 28 days before the start of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Concurrent anticancer treatment (with the exception of palliative bone directed radiotherapy)",
                    "criterion": "concurrent anticancer treatment",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "palliative bone directed radiotherapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "immune therapy, or cytokine therapy (except for erythropoietin)",
                    "criterion": "concurrent immune therapy or cytokine therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "erythropoietin"
                        }
                    ]
                },
                {
                    "exact_snippets": "major surgery (excluding prior diagnostic biopsy)",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "prior diagnostic biopsy"
                        }
                    ]
                },
                {
                    "exact_snippets": "concurrent systemic therapy with steroids or other immunosuppressive agents",
                    "criterion": "concurrent systemic therapy with steroids or other immunosuppressive agents",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "use of any investigational drug within 28 days before the start of study treatment",
                    "criterion": "use of investigational drug",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Rapidly progressive disease",
            "criterions": [
                {
                    "exact_snippets": "Rapidly progressive disease",
                    "criterion": "disease progression rate",
                    "requirements": [
                        {
                            "requirement_type": "rate",
                            "expected_value": "rapid"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with DF6002, recombinant human interleukin-12 (rhIL-12)-directed therapy, or any drug containing an interleukin-12 (IL-12) moiety",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with DF6002",
                    "criterion": "prior treatment with DF6002",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with ... recombinant human interleukin-12 (rhIL-12)-directed therapy",
                    "criterion": "prior treatment with recombinant human interleukin-12 (rhIL-12)-directed therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with ... any drug containing an interleukin-12 (IL-12) moiety",
                    "criterion": "prior treatment with any drug containing an interleukin-12 (IL-12) moiety",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known diagnosis of antiphospholipid syndrome or clinically significant hereditary thrombophilia",
            "criterions": [
                {
                    "exact_snippets": "Known diagnosis of antiphospholipid syndrome",
                    "criterion": "antiphospholipid syndrome",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant hereditary thrombophilia",
                    "criterion": "hereditary thrombophilia",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previous malignant disease other than the current target malignancy within the last 3 years, with the exception of basal or squamous cell carcinoma of the skin, localized prostate cancer or cervical carcinoma in situ",
            "criterions": [
                {
                    "exact_snippets": "Previous malignant disease other than the current target malignancy within the last 3 years",
                    "criterion": "previous malignant disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": "other than the current target malignancy"
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of basal or squamous cell carcinoma of the skin, localized prostate cancer or cervical carcinoma in situ",
                    "criterion": "previous malignant disease type",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": [
                                "basal cell carcinoma of the skin",
                                "squamous cell carcinoma of the skin",
                                "localized prostate cancer",
                                "cervical carcinoma in situ"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Serious cardiac illness or medical conditions",
            "criterions": [
                {
                    "exact_snippets": "Serious cardiac illness",
                    "criterion": "cardiac illness",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "serious"
                        }
                    ]
                },
                {
                    "exact_snippets": "serious ... medical conditions",
                    "criterion": "medical conditions",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "serious"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}